CompletedPhase 2NCT00901199
Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload
Studying Rare hereditary hemochromatosis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Elliott Vichinsky
- Principal Investigator
- Elliot Vichinsky, MDUCSF Benioff Children's Hospital Oakland
- Intervention
- Combo Chelation with Deferasirox (Exjade) and Deferoxamine (DFO)(drug)
- Enrollment
- 22 enrolled
- Eligibility
- 8 years · All sexes
- Timeline
- 2007 – 2012
Study locations (1)
- CHRCO, Oakland, California, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00901199 on ClinicalTrials.govOther trials for Rare hereditary hemochromatosis
Additional recruiting or active studies for the same condition.